Walter Blättler
Chairman at Formation Biologics Corp.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ilia Tikhomirov | M | - |
Bristol-Myers Squibb FCT bêta, Inc.
 Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada.
Formation Biologics Corp.
 Formation Biologics Corp. Miscellaneous Commercial ServicesCommercial Services Formation Biologics Corp. operates as a biopharmaceutical drug development company. It discovers and develops drugs and medicines for treatment of patients with cancers and orphan diseases. The company was founded in 2011 and is headquartered in Austin, TX.
35Pharma, Inc.
 35Pharma, Inc. Pharmaceuticals: MajorHealth Technology 35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov. | 10 years |
| Gregg Beloff | M | 56 |
Bristol-Myers Squibb FCT bêta, Inc.
Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada.
35Pharma, Inc.
35Pharma, Inc. Pharmaceuticals: MajorHealth Technology 35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov.
Formation Biologics Corp.
Formation Biologics Corp. Miscellaneous Commercial ServicesCommercial Services Formation Biologics Corp. operates as a biopharmaceutical drug development company. It discovers and develops drugs and medicines for treatment of patients with cancers and orphan diseases. The company was founded in 2011 and is headquartered in Austin, TX. | 6 years |
| Marc Cluzel | M | 69 | 12 years | |
| Renee Lentini | F | 46 | 20 years | |
| Joerg Gruber | M | 63 |
Bristol-Myers Squibb FCT bêta, Inc.
Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada.
Formation Biologics Corp.
Formation Biologics Corp. Miscellaneous Commercial ServicesCommercial Services Formation Biologics Corp. operates as a biopharmaceutical drug development company. It discovers and develops drugs and medicines for treatment of patients with cancers and orphan diseases. The company was founded in 2011 and is headquartered in Austin, TX. | 9 years |
| Maureen O’Connor | M | - |
35Pharma, Inc.
35Pharma, Inc. Pharmaceuticals: MajorHealth Technology 35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov. | - |
| Cédric Bisson | M | - |
35Pharma, Inc.
35Pharma, Inc. Pharmaceuticals: MajorHealth Technology 35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov. | - |
| Charlotte Lohmann | F | 54 | 12 years | |
| Aaron Royston | M | 40 |
35Pharma, Inc.
35Pharma, Inc. Pharmaceuticals: MajorHealth Technology 35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov. | - |
| Richard Gaster | M | 40 |
35Pharma, Inc.
35Pharma, Inc. Pharmaceuticals: MajorHealth Technology 35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Daniel Junius | M | 71 | 13 years | |
| Karl W. Gschwend | M | 71 |
Swiss Federal Institute of Technology
| 9 years |
| Stephen McCluski | M | 72 | 17 years | |
| Ernst A. Häberli | M | 75 |
Swiss Federal Institute of Technology
| 4 years |
| Andreas Plückthun | M | 65 | 15 years | |
| Klaus Kühn | M | 72 | 3 years | |
| Alexandra Goller | F | - | - | |
| Wendy Johnson | F | 72 | 7 years | |
| Jürgen Drews | M | 91 | 14 years | |
| Daniel Camus | M | 70 | 12 years | |
| Ludger Langer | M | - | - | |
| Geoffrey Nicholas Vernon | M | 72 | 16 years | |
| David Warren Carter | M | 84 | 14 years | |
| Metin Colpan | M | 69 | 8 years | |
| Victor Waldemar Balli | M | 67 |
Swiss Federal Institute of Technology
| 5 years |
| John M. Lambert | M | 72 | - | |
| Joseph J. Villafranca | M | 79 | 14 years | |
| Karin Eastham | F | 74 | 5 years | |
| Frank Morich | M | 69 | 5 years | |
| Mark B. Skaletsky | M | 75 | 13 years | |
| Nicole Onetto | M | 71 | 11 years | |
| Mehmet Tara | M | 66 |
Swiss Federal Institute of Technology
| 4 years |
| Gabriele Elbl | M | 62 | 5 years | |
| Stephen Yoder | M | 48 | 11 years | |
| Periclès–Paul P. Petalas | M | 81 |
Swiss Federal Institute of Technology
| 1 years |
| François Meyer | M | 76 |
Swiss Federal Institute of Technology
| 4 years |
| Jost Krüttli | M | 73 |
Swiss Federal Institute of Technology
| 4 years |
| Peter Baumann | M | 68 |
Swiss Federal Institute of Technology
| 4 years |
| Pierre-François Veillon | M | 74 |
Swiss Federal Institute of Technology
| 1 years |
| Hans-Rudolf Spiess | M | 75 |
Swiss Federal Institute of Technology
| 3 years |
| Michel Perraudin | M | 78 |
Swiss Federal Institute of Technology
| 4 years |
| Jens Holstein | M | 60 | 9 years | |
| Peter Krebser | M | 72 |
Swiss Federal Institute of Technology
| 9 years |
| Anthony William Tolcher | M | - |
Bristol-Myers Squibb FCT bêta, Inc.
Bristol-Myers Squibb FCT bêta, Inc. Pharmaceuticals: MajorHealth Technology Bristol-Myers Squibb FCT bêta, Inc. operates as a biopharmaceutical firm. It develops anti-tumor activity medication treatment. The company was founded by Ilia A. Tikhomirov in 2011 and is headquartered in Toronto, Canada. | - |
| Juerg Winter | M | - |
Swiss Federal Institute of Technology
| 3 years |
| Jean-Daniel Borgeaud | M | 66 |
Swiss Federal Institute of Technology
| 4 years |
| Alfons Traxler | M | - |
Swiss Federal Institute of Technology
| 4 years |
| Veli Ergin Imre | M | 66 |
Swiss Federal Institute of Technology
| 4 years |
| Martin Clark | M | - | - | |
| Alexander Jakob Boris Zehnder | M | - |
Swiss Federal Institute of Technology
| 3 years |
| Simon Jones | M | - |
Swiss Federal Institute of Technology
| 4 years |
| Robert Friesen | M | 60 | 3 years | |
| Laurent Vulliet | M | 66 |
Swiss Federal Institute of Technology
| 4 years |
| Jacques de Saussure | M | - |
Swiss Federal Institute of Technology
| 4 years |
| Hans Brändle | M | 63 |
Swiss Federal Institute of Technology
| 14 years |
| Robert Lutz | M | - | 23 years | |
| Caroline Geuissaz | F | - |
Swiss Federal Institute of Technology
| 4 years |
| Cynthia Seidel-Dugan | M | 65 |
CoStim Pharmaceuticals, Inc.
 CoStim Pharmaceuticals, Inc. BiotechnologyHealth Technology CoStim Pharmaceuticals, Inc. operates as a biotech company which develops biologics for oncology indications. It offers therapies which target immune checkpoint inhibitors for novel treatment. The company was founded on February 01, 2013 and is headquartered in Boston, MA. | 1 years |
| Duccio Alberti | M | 72 |
Swiss Federal Institute of Technology
| 3 years |
| Felix Bärlocher | M | 76 |
Swiss Federal Institute of Technology
| 4 years |
| Carl Erik Steen | M | 74 |
Swiss Federal Institute of Technology
| 1 years |
| Peter H. Müller | M | 74 |
Swiss Federal Institute of Technology
| 1 years |
| Martin Bachmann | M | 65 |
Swiss Federal Institute of Technology
| 5 years |
| James Ambrose Taylor | M | 85 | 5 years | |
| Dan Hicklin | M | 61 |
CoStim Pharmaceuticals, Inc.
CoStim Pharmaceuticals, Inc. BiotechnologyHealth Technology CoStim Pharmaceuticals, Inc. operates as a biotech company which develops biologics for oncology indications. It offers therapies which target immune checkpoint inhibitors for novel treatment. The company was founded on February 01, 2013 and is headquartered in Boston, MA. | 1 years |
| Karleen Oberton | F | 54 | 2 years | |
| Jean-Christophe Hadorn | M | 67 |
Swiss Federal Institute of Technology
| 1 years |
| Pauline Jen Ryan | F | - | 8 years | |
| Sergio Magistri | M | - |
Swiss Federal Institute of Technology
| 4 years |
| Pierre de Weck | M | 73 |
Swiss Federal Institute of Technology
| 1 years |
| David Lemus | M | 61 | 13 years | |
| Christoph Alexander Schoeller | M | 65 |
Swiss Federal Institute of Technology
| 4 years |
| Armin Meyer | M | 75 |
Swiss Federal Institute of Technology
| 3 years |
| Roger D. Kitterman | M | - |
CoStim Pharmaceuticals, Inc.
CoStim Pharmaceuticals, Inc. BiotechnologyHealth Technology CoStim Pharmaceuticals, Inc. operates as a biotech company which develops biologics for oncology indications. It offers therapies which target immune checkpoint inhibitors for novel treatment. The company was founded on February 01, 2013 and is headquartered in Boston, MA. | 2 years |
| Andreas Niklaus Koopmann-Zulliger | M | 73 |
Swiss Federal Institute of Technology
| 1 years |
| Bernhard Jucker | M | 70 |
Swiss Federal Institute of Technology
| 4 years |
| Peter Leupp | M | 72 |
Swiss Federal Institute of Technology
| 4 years |
| Fritz Gantert | M | 66 |
Swiss Federal Institute of Technology
| 5 years |
| Carol Hausner | F | - | - | |
| Reto Crameri | M | - |
Swiss Federal Institute of Technology
| 3 years |
| Jürg Spillmann | M | - |
Swiss Federal Institute of Technology
| 4 years |
| John Tagliamonte | M | 57 | 1 years | |
| Heinrich Andreas Baumann | M | 72 |
Swiss Federal Institute of Technology
| 4 years |
| Niklaus Peter Nüesch | M | 70 |
Swiss Federal Institute of Technology
| 7 years |
| Antonio Matteo Taormina | M | 76 |
Swiss Federal Institute of Technology
| 4 years |
| Romain Becker | M | 70 |
Swiss Federal Institute of Technology
| 4 years |
| Giovanni Müller | M | - |
Swiss Federal Institute of Technology
| 4 years |
| Erwin Stoller | M | 77 |
Swiss Federal Institute of Technology
| 1 years |
| Daniel Crausaz | M | 67 |
Swiss Federal Institute of Technology
| 4 years |
| Thomas Villiger | M | 73 |
Swiss Federal Institute of Technology
| 3 years |
| Jakob Züger | M | 72 |
Swiss Federal Institute of Technology
| 1 years |
| Peter Gnägi | M | 70 |
Swiss Federal Institute of Technology
| 4 years |
| Michel Streuli | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Switzerland | 48 | 51.61% |
| United States | 21 | 22.58% |
| Germany | 19 | 20.43% |
| Canada | 8 | 8.60% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Walter Blättler
- Personal Network
